Compare VLYPO & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B
Current Price
| Metric | VLYPO | TGTX |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | United States |
| Employees | 3732 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 5.5B |
| IPO Year | N/A | 1995 |
| Metric | VLYPO | TGTX |
|---|---|---|
| Price | $25.17 | $31.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $54.75 |
| AVG Volume (30 Days) | N/A | ★ 1.6M |
| Earning Date | N/A | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $531,898,000.00 |
| Revenue This Year | N/A | $87.88 |
| Revenue Next Year | N/A | $48.75 |
| P/E Ratio | ★ N/A | $11.16 |
| Revenue Growth | N/A | ★ 100.88 |
| 52 Week Low | N/A | $25.28 |
| 52 Week High | N/A | $46.48 |
| Indicator | VLYPO | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.89 | 48.42 |
| Support Level | $24.96 | $29.79 |
| Resistance Level | $25.59 | $32.30 |
| Average True Range (ATR) | 0.17 | 1.09 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 40.00 | 61.38 |
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.